|
GB929401A
(en)
|
1958-12-22 |
1963-06-19 |
Upjohn Co |
Encapsulated emulsions and processes for their preparation
|
|
GB929405A
(en)
|
1958-12-22 |
1963-06-19 |
Upjohn Co |
Processes for the encapsulation of particles
|
|
GB969808A
(en)
|
1962-06-08 |
1964-09-16 |
Boots Pure Drug Co Ltd |
Anthelmintic compositions and compounds
|
|
IT1148784B
(it)
|
1980-04-09 |
1986-12-03 |
Eurand Spa |
Procedimento per la preparazione di microcapsule in un veicolo liquido
|
|
US4794000A
(en)
|
1987-01-08 |
1988-12-27 |
Synthetic Blood Corporation |
Coacervate-based oral delivery system for medically useful compositions
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
US4997652A
(en)
|
1987-12-22 |
1991-03-05 |
Visionex |
Biodegradable ocular implants
|
|
US4991920A
(en)
|
1988-12-27 |
1991-02-12 |
Andrzej Peczalski |
Optical converter
|
|
US5019400A
(en)
|
1989-05-01 |
1991-05-28 |
Enzytech, Inc. |
Very low temperature casting of controlled release microspheres
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
US5441722A
(en)
|
1994-02-18 |
1995-08-15 |
Merck & Co., Inc. |
Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
AU4755696A
(en)
|
1995-01-05 |
1996-07-24 |
Board Of Regents Acting For And On Behalf Of The University Of Michigan, The |
Surface-modified nanoparticles and method of making and using same
|
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
|
US6566406B1
(en)
|
1998-12-04 |
2003-05-20 |
Incept, Llc |
Biocompatible crosslinked polymers
|
|
US6201072B1
(en)
|
1997-10-03 |
2001-03-13 |
Macromed, Inc. |
Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
|
|
US6841617B2
(en)
|
2000-09-28 |
2005-01-11 |
Battelle Memorial Institute |
Thermogelling biodegradable aqueous polymer solution
|
|
US6632457B1
(en)
|
1998-08-14 |
2003-10-14 |
Incept Llc |
Composite hydrogel drug delivery systems
|
|
US6703047B2
(en)
|
2001-02-02 |
2004-03-09 |
Incept Llc |
Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
|
|
US6818018B1
(en)
|
1998-08-14 |
2004-11-16 |
Incept Llc |
In situ polymerizable hydrogels
|
|
US20040258763A1
(en)
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
WO2002036169A2
(en)
|
2000-10-31 |
2002-05-10 |
Pr Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
|
US7060299B2
(en)
|
2002-12-31 |
2006-06-13 |
Battelle Memorial Institute |
Biodegradable microparticles that stabilize and control the release of proteins
|
|
WO2004084819A2
(en)
*
|
2003-03-19 |
2004-10-07 |
University Of Kentucky Research Foundation |
Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
|
|
GB0307011D0
(en)
|
2003-03-27 |
2003-04-30 |
Regentec Ltd |
Porous matrix
|
|
DK1635875T3
(da)
|
2003-06-26 |
2009-01-12 |
Psivida Inc |
In-situ-geldannende lægemiddeladministrationssystem
|
|
US20090148527A1
(en)
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
US8685435B2
(en)
*
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
US20050244472A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
|
US7771742B2
(en)
*
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
WO2007030545A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Southwest Research Institute |
Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates
|
|
US7501179B2
(en)
|
2005-12-21 |
2009-03-10 |
Boston Scientific Scimed, Inc. |
Block copolymer particles
|
|
US20070149593A1
(en)
|
2005-12-23 |
2007-06-28 |
Alcon, Inc. |
PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
|
|
JP5819579B2
(ja)
|
2006-01-13 |
2015-11-24 |
サーモディクス，インコーポレイティド |
薬物送達のためのマトリックスを含む微粒子
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
US20100215580A1
(en)
|
2006-09-08 |
2010-08-26 |
The Johns Hopkins University |
Compositions and methods for enhancing transport through mucus
|
|
GB0619869D0
(en)
|
2006-10-07 |
2006-11-15 |
Regentec Ltd |
Porous particles
|
|
BRPI0718696A2
(pt)
|
2006-11-09 |
2013-12-31 |
Alcon Res Ltd |
Matriz de polímero insolúvel em água para liberação de fármaco.
|
|
GB0701896D0
(en)
|
2007-02-01 |
2007-03-14 |
Regentec Ltd |
Composition
|
|
JP2010519183A
(ja)
|
2007-02-06 |
2010-06-03 |
インセプト エルエルシー |
生理溶液の溶出のためのタンパク質の沈殿を用いる重合
|
|
WO2008157614A2
(en)
|
2007-06-21 |
2008-12-24 |
Yale University |
Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
|
|
CN101081206A
(zh)
*
|
2007-06-29 |
2007-12-05 |
济南康泉医药科技有限公司 |
一种含酪氨酸激酶抑制剂的抗癌药物组合物
|
|
US9125807B2
(en)
|
2007-07-09 |
2015-09-08 |
Incept Llc |
Adhesive hydrogels for ophthalmic drug delivery
|
|
AU2008315318B2
(en)
|
2007-10-26 |
2014-02-06 |
National Institute Of Immunology |
Biodegradable polymer scaffold and process for preparation thereof
|
|
US20090203709A1
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
|
|
CA2717133C
(en)
|
2008-02-29 |
2016-04-26 |
Nagoya Industrial Science Research Institute |
Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
|
|
CN101336890A
(zh)
|
2008-05-30 |
2009-01-07 |
济南基福医药科技有限公司 |
一种抗癌缓释凝胶注射剂
|
|
WO2010017541A2
(en)
*
|
2008-08-08 |
2010-02-11 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
|
US20100063135A1
(en)
|
2008-09-10 |
2010-03-11 |
Abbott Laboratories |
Polyethylene glycol lipid conjugates and uses thereof
|
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
|
RU2532345C2
(ru)
|
2009-01-12 |
2014-11-10 |
Хадасит Медикэл Рисёч Сервисес Энд Девелопмент Лимитэд |
Мембрана для регенерации ткани
|
|
EP2391419B1
(en)
|
2009-01-29 |
2019-06-12 |
ForSight Vision4, Inc. |
Posterior segment drug delivery
|
|
US20120052041A1
(en)
|
2009-02-04 |
2012-03-01 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
EP2396070B1
(en)
|
2009-02-12 |
2024-12-04 |
Incept Llc |
Drug delivery through hydrogel plugs
|
|
KR20160135372A
(ko)
|
2009-03-03 |
2016-11-25 |
알콘 리서치, 리미티드 |
리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
|
|
GB0903810D0
(en)
|
2009-03-05 |
2009-04-22 |
Regentec Ltd |
Delivery system
|
|
WO2010114770A1
(en)
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
|
EP3583960A1
(en)
|
2009-12-15 |
2019-12-25 |
Incept, LLC |
Implants and biodegradable fiducial markers
|
|
CA2791278C
(en)
*
|
2010-02-25 |
2015-11-24 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
|
US20130071349A1
(en)
|
2010-03-02 |
2013-03-21 |
Allergan, Inc. |
Biodegradable polymers for lowering intraocular pressure
|
|
US9162981B2
(en)
|
2010-03-23 |
2015-10-20 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
|
US20110237686A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
|
US8961501B2
(en)
|
2010-09-17 |
2015-02-24 |
Incept, Llc |
Method for applying flowable hydrogels to a cornea
|
|
AU2011323250B2
(en)
|
2010-11-05 |
2015-11-19 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
|
US9327037B2
(en)
|
2011-02-08 |
2016-05-03 |
The Johns Hopkins University |
Mucus penetrating gene carriers
|
|
US9382229B2
(en)
|
2011-02-15 |
2016-07-05 |
The Johns Hopkins University |
Compounds and methods of use thereof for treating neurodegenerative disorders
|
|
US10226417B2
(en)
|
2011-09-16 |
2019-03-12 |
Peter Jarrett |
Drug delivery systems and applications
|
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
|
JP6199883B2
(ja)
|
2011-12-05 |
2017-09-20 |
インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ |
医療用オルガノゲルプロセス及び組成物
|
|
WO2013090804A2
(en)
|
2011-12-14 |
2013-06-20 |
The Johns Hopkins University |
Nanoparticles with enhanced mucosal penetration or decreased inflammation
|
|
CA2863632C
(en)
|
2012-01-19 |
2017-07-11 |
The Johns Hopkins University |
Nanoparticle formulations with enhanced mucosal penetration
|
|
US10159743B2
(en)
|
2012-03-16 |
2018-12-25 |
The Johns Hopkins University |
Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
|
|
EP2825206A1
(en)
|
2012-03-16 |
2015-01-21 |
The Johns Hopkins University |
Controlled release formulations for the delivery of hif-1 inhibitors
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
HK1208162A1
(en)
|
2012-05-03 |
2016-02-26 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
NZ728721A
(en)
|
2012-05-03 |
2018-05-25 |
Kala Pharmaceuticals Inc |
Pharmaceutical nanoparticles showing improved mucosal transport
|
|
US9533068B2
(en)
|
2012-05-04 |
2017-01-03 |
The Johns Hopkins University |
Drug loaded microfiber sutures for ophthalmic application
|
|
US9889208B2
(en)
|
2012-05-04 |
2018-02-13 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
|
EP2852388A4
(en)
*
|
2012-05-23 |
2016-01-13 |
Univ Johns Hopkins |
COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
WO2013188283A1
(en)
*
|
2012-06-12 |
2013-12-19 |
Bayer Healthcare Llc |
Topical ophthalmological pharmaceutical composition containing sunitinib
|
|
CA2885022A1
(en)
*
|
2012-09-17 |
2014-03-20 |
Bind Therapeutics, Inc. |
Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
|
|
CN103848985B
(zh)
*
|
2012-11-30 |
2018-03-02 |
杨子剑 |
含有舒尼替尼类似物结构的新化合物以及制备方法和用途
|
|
EP2981248B1
(en)
|
2013-04-01 |
2020-09-02 |
Allergan, Inc. |
Microsphere drug delivery system for sustained intraocular release
|
|
CN104208715B
(zh)
|
2013-05-31 |
2016-12-28 |
天津键凯科技有限公司 |
具有提高的药物生物活性的低分子量聚乙二醇药物结合物
|
|
US20160372268A1
(en)
|
2013-06-18 |
2016-12-22 |
Showa Denko K.K. |
Capacitor anode and production method for same
|
|
US10646027B2
(en)
|
2013-08-29 |
2020-05-12 |
Sayeeda Mazed |
Multifunctional personal care devices/apparatuses and compositions for hair or skin
|
|
US20160310417A1
(en)
|
2013-12-20 |
2016-10-27 |
Emory University |
Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
|
|
KR101564401B1
(ko)
|
2014-04-10 |
2015-11-02 |
한국화학연구원 |
브린졸아마이드의 제조방법
|
|
KR20170046146A
(ko)
|
2014-08-13 |
2017-04-28 |
더 존스 홉킨스 유니버시티 |
각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자
|
|
US20160106587A1
(en)
|
2014-10-16 |
2016-04-21 |
Incept, Llc |
Ocular gels or hydrogels and microinjectors
|
|
US10550187B2
(en)
|
2014-10-24 |
2020-02-04 |
Incept, Llc |
Extra luminal scaffold
|
|
KR20170117384A
(ko)
|
2014-12-10 |
2017-10-23 |
인셉트, 엘엘씨 |
히드로겔 약물 전달 임플란트
|
|
RU2729731C2
(ru)
*
|
2014-12-15 |
2020-08-11 |
Зе Джонс Хопкинс Юниверсити |
Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
|
|
JP6479485B2
(ja)
|
2015-01-15 |
2019-03-06 |
大内新興化学工業株式会社 |
眼疾患治療用ナノ粒子製剤
|
|
JP2018503736A
(ja)
|
2015-01-20 |
2018-02-08 |
ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ |
眼内圧を抑える抗緑内障剤の持続放出のための組成物
|
|
MX385405B
(es)
|
2015-05-05 |
2025-03-18 |
Eyepoint Pharmaceuticals Us Inc |
Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
|
|
EP3294212B1
(en)
|
2015-05-12 |
2023-10-25 |
Incept, LLC |
Drug delivery from hydrogels
|
|
US10617563B2
(en)
|
2015-07-22 |
2020-04-14 |
Incept, Llc |
Coated implants
|
|
US10420724B2
(en)
|
2015-11-25 |
2019-09-24 |
Incept, Llc |
Shape changing drug delivery devices and methods
|